ricefidase (KJ103) - Shanghai Bao Pharma, KisoJi Biotech
Rituxan (rituximab) - Roche
Durable B-Cell Depletion After Ricefidase-Mediated IgG Cleavage Using a Protease-Resistant Anti-CD20 Antibody for Transplant Desensitization and Antibody-Mediated Rejection (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0986; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Ricefidase (KJ103) is an IgG-degrading enzyme capable of rapidly eliminating circulating IgG antibodies. By combining rapid pathogenic IgG elimination with prolonged B-cell depletion, this regimen may offer a practical and potentially more effective alternative to plasma exchange plus rituximab. The approach may also have broader applications in acute antibody-mediated autoimmune diseases requiring rapid IgG removal and durable suppression of autoreactive B cells." 
Antibody-mediated Rejection • Immunology • Transplantation
https://www.asn-online.org/education/kidneyweek/2026/program-abstract.aspx?controlId=4560017
 
Chaoyue Yan; Yunxia Xu; Zhen Zhu; Yanjun Liu
 
Oct 2, 2026
 
Prev Next